Association Study between Novel CYP26 Polymorphisms and the Risk of Betel Quid-Related Malignant Oral Disorders
Table 3
Joint effects between CYP26A1 and CYP26B1 polymorphisms among malignant oral disorders patients and control groups.
Oral and pharyngeal cancer ()
OPMDs ()
Controls ()
Oral and pharyngeal cancer versus controls
OPMDs versus controls
BQ chewers
(%)
(%)
(%)
aOR (95% CI)
aOR (95% CI)
CYP26A1 rs4411227
CYP26B1 rs887844
Allele
Allele
G
G
272 (64.45)
75 (66.96)
298 (68.35)
1.00
C
G
54 (12.80)
6 (5.36)
53 (12.16)
1.13 (0.72–1.76)
0.39 (0.15–1.02)
G
A
62 (14.69)
19 (16.96)
85 (19.50)
0.83 (0.56–1.23)
0.90 (0.50–1.62)
C
A
34 (8.06)
12 (10.71)
0 (0.00)
—a
—a
CYP26A1 rs4411227
CYP26B1 rs3768647
Allele
Allele
G
C
62 (14.69)
26 (23.21)
170 (38.99)
1.00
1.00
C
C
41 (9.72)
8 (7.14)
48 (11.01)
2.51 (1.45–4.34)b*
1.17 (0.48–2.82)
G
G
272 (64.45)
68 (60.71)
213 (48.85)
3.64 (2.51–5.26)*
2.14 (1.28–3.59)*
C
G
47 (11.14)
10 (8.93)
5 (1.15)
29.91 (10.75–83.23)*
11.25 (3.18–39.77)*
CYP26A1 rs4411227
CYP26B1 rs9309462
Allele
Allele
G
T
327 (77.49)
92 (82.14)
382 (87.61)
1.00
1.00
C
T
82 (19.43)
16 (14.29)
52 (11.93)
1.85 (1.23–2.77)*
1.07 (0.55–2.08)
G
C
7 (1.66)
2 (1.79)
1 (0.23)
9.44 (1.08–82.43)*
4.58 (0.27–77.85)
C
C
6 (1.42)
2 (1.79)
1 (0.23)
10.03 (1.05–95.60)*
12.20 (0.99–151.07)
aOR was adjusted by continuous age, ethnicity, education level, alcohol drinking, and cigarette smoking habits.
aNonestimated: because the number of samples is equal to zero.
